DEA Revokes Colorado Doctor's Controlled Substance License
Published Date: 2/14/2025
Notice
Summary
Dr. Yogesh Patel from Colorado lost his DEA registration because he’s not allowed to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration starting early 2024. This means Dr. Patel can no longer legally prescribe or manage controlled drugs, affecting his medical practice and patients.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Patel
The DEA revoked Yogesh Patel, M.D.'s Certificate of Registration No. FP8684931, effective March 17, 2025. He can no longer lawfully prescribe, dispense, or handle controlled substances in Colorado, which affects his medical practice and his patients' access to controlled medications.
Pending DEA Applications Denied
The DEA denied any pending applications by Yogesh Patel, M.D., to renew or modify his registration and denied any other pending applications for additional registration in Colorado. This prevents him from restoring or obtaining DEA authority to handle controlled substances in Colorado.
15-Day Reconsideration Window
Dr. Patel may file a properly supported motion for reconsideration of the Agency's findings of fact within fifteen calendar days of the date of this Order by email to the DEA Office of the Administrator. A timely motion gives him an opportunity to dispute the Agency's finding that his Colorado license is restricted.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-02626 — Provo River Project-Rate Order No. WAPA-221
The Provo River Project’s electric service rate formula got a fresh update that kicks in right away! This new formula replaces the old one starting now but keeps the prices steady until March 31, 2025. If you’re using this power, nothing changes except some contract details getting a tidy refresh.
Next: 2025-02631 — Procurement List; Proposed Deletions
The government plans to remove some products and services from a special list that nonprofit groups, which help people with disabilities, currently provide. This change means those groups might lose contracts soon. If you’re involved, keep an eye on deadlines and budget updates to stay ahead!